SAN DIEGO, March 11, 2013 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") announced today that its Chief Scientific Officer, Benjamin Sullivan, Ph.D., will present an update on the Company's business at the 25th Annual ROTH Conference on Monday, March 18, 2013 at 11:00 a.m. Pacific Time. The conference will be held at The Ritz Carlton in Dana Point, CA. Dr. Sullivan's presentation will be webcast live and archived for at least 30 days on the Company's website at http://www.tearlab.com under the "Webcasts" tab in the Investors section. About TearLab Corporation TearLab Corporation ( www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Forward-Looking Statements This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding future success of our "3/15" and "3/24" marketing programs, the future commercial adoption of the TearLab ® Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
CONTACT: Investors Stephen Kilmer 647.872.4849 email@example.com